FMFernando Centeno Malfaz

Fernando Centeno Malfaz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fernando Centeno Malfaz has a total of 183 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comunicación interauricular en edad pediátrica: características clínicas, manejo y resultados

    by Elisa Martín Pérez, Mateo José Jiménez Noriega, Carlos Alcalde Martín, Garazi Fraile Astorga, Fernando Centeno Malfaz, Beatriz Salamanca Zarzuela

    Introduction and objectives: Atrial septal defects (ASDs) account for 6-10% of congenital heart defects. The most prevalent type, with the most variable clinical and therapeutic approach, is the ostium secundum(OS). The objective of this study is to describe the clinical and evolutionary characteristics, as well as the clinical and echocardiographic prognostic factors, of patients requiring closure of the defect. Materials and methods: Retrospective observational study of patients diagnosed with ASD. Variables studied: ASD type, size, age at diagnosis and at closure, and type of closure. Results: Predominance in males(55.4%), with OS being the most frequent(80.3%). 25% presented with heart failure during their follow-up, and 24.2% required nutritional support. At diagnosis, the mean age and size were 17.71 months and 6.5 mm. Spontaneous closure occurred in 15.2%, closure was achieved with a device in 24.2%, surgical closure was required in 30.3%. Ostium primum(OP) and sinus venosus(SV) ASDs required external closure. Age at closure was not a significant factor, but OS and SV were larger. OS ASDs were analyzed, revealing a 2.5-fold increased risk in males and a 7.33-fold increased risk of requiring closure in sizes >5 mm at diagnosis. No factors were found to indicate a preference for surgical or device-assisted closure. Conclusions: The most frequent ASD was type OS, with closure being more frequently in males and in those with a size greater than 5 mm at diagnosis, without finding prognostic factors for the type of closure. All OP and venous sinus ASDs required surgical closure.

  • Open Access

    Relationship Between Maximal Left Ventricular Wall Thickness and Sudden Cardiac Death in Childhood Onset Hypertrophic Cardiomyopathy

    by Gabrielle Norrish, Tao Ding, Ella Field, Elena Cervi, Lidia Ziółkowska, Iacopo Olivotto, Diala Khraiche, Giuseppe Limongelli, Aris Anastasakis, Robert Weintraub, et al.

    Background: Maximal left ventricular wall thickness (MLVWT) is a risk factor for sudden cardiac death (SCD) in hypertrophic cardiomyopathy (HCM). In adults, the severity of left ventricular hypertrophy has a nonlinear relationship with SCD, but it is not known whether the same complex relationship is seen in childhood. The aim of this study was to describe the relationship between left ventricular hypertrophy and SCD risk in a large international pediatric HCM cohort. Methods: The study cohort comprised 1075 children (mean age, 10.2 years [±4.4]) diagnosed with HCM (1–16 years) from the International Paediatric Hypertrophic Cardiomyopathy Consortium. Anonymized, noninvasive clinical data were collected from baseline evaluation and follow-up, and 5-year estimated SCD risk was calculated (HCM Risk-Kids). Results: MLVWT Z score was Z scores were associated with heart failure symptoms, unexplained syncope, left ventricular outflow tract obstruction, left atrial dilatation, and nonsustained ventricular tachycardia. One hundred twenty-two patients (71.3%) with MLVWT Z score ≥20 had coexisting risk factors for SCD. Over a median follow-up of 4.9 years (interquartile range, 2.3–9.3), 115 (10.7%) had an SCD event. Freedom from SCD event at 5 years for those with MLVWT Z scores Z score, peaking at Z score +23. The presence of coexisting risk factors had a summative effect on risk. Conclusions: In children with HCM, an inverted U-shaped relationship exists between left ventricular hypertrophy and estimated SCD risk. The presence of additional risk factors has a summative effect on risk. While MLVWT is important for risk stratification, it should not be used either as a binary variable or in isolation to guide implantable cardioverter defibrillator implantation decisions in children with HCM.


  • Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib and PHiD-CV When Coadministered With MenACWY-TT in Infants

    by Jose Manuel Merino Arribas, Alfonso Carmona Martínez, Michael Horn, Xavier Maria Perez Porcuna, Maria del Carmen Otero Reigada, Josep Marès Bermúdez, Fernando Centeno Malfaz, Mariano Miranda, Maria Mendez, Miguel Angel Garcia Cabezas, et al.

    Background: This study evaluated the immunogenicity and reactogenicity of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus virus-Haemophilus influenzae type b vaccine (DTPa-HBV-IPV/Hib) and a 10-valent pneumococcal conjugate vaccine (PHiD-CV) coadministered with a quadrivalent meningococcal conjugate vaccine (MenACWY-TT) in infants/toddlers. Methods: In this open, controlled, phase III study (NCT01144663), 2095 healthy infants were randomized (1:1:1:1) into 4 groups to receive MenACWY-TT at 2, 3, 4 and 12 months of age or MenACWY-TT, MenC-CRM197, or MenC-TT at 2, 4 and 12 months of age. All participants received PHiD-CV and DTPa-HBV-IPV/Hib at 2, 3, 4 and 12 months of age. Immunogenicity of DTPa-HBV-IPV/Hib was evaluated in exclusive randomized subsets of 25% of participants from each group postprimary, prebooster and postbooster vaccination, whereas immunogenicity of PHiD-CV was evaluated at all time points. Reactogenicity was evaluated on the total vaccinated cohorts during 8 days after each vaccination. Results: For each DTPa-HBV-IPV/Hib antigen, ≥97.2%, ≥76.5% and ≥97.9% of participants had seropositive/seroprotective levels 1 month postprimary vaccination, before the booster dose and 1 month postbooster, respectively. For each vaccine pneumococcal serotype, ≥74.0% of infants had antibody concentrations ≥0.35 μg/mL at 1 month postprimary vaccination, and robust increases in antibody geometric mean concentrations were observed from prebooster to postbooster. Redness was the most frequent solicited local symptom at the DTPa-HBV-IPV/Hib and PHiD-CV injection sites, reported after up to 47.7% and 57.0% of doses postprimary and postbooster vaccination, respectively. Conclusions: Primary and booster vaccinations of infants/toddlers with DTPa-HBV-IPV/Hib and PHiD-CV coadministered with MenACWY-TT were immunogenic with clinically acceptable reactogenicity profiles. These results support the coadministration of MenACWY-TT with routine childhood vaccines.


  • Safety and Immunogenicity of the Quadrivalent Meningococcal Serogroups A, C, W and Y Tetanus Toxoid Conjugate Vaccine Coadministered With Routine Childhood Vaccines in European Infants

    by Jose Manuel Merino Arribas, Alfonso Carmona Martínez, Michael Horn, Xavier Maria Perez Porcuna, Maria del Carmen Otero Reigada, Josep Marès Bermúdez, Fernando Centeno Malfaz, Mariano Miranda, Maria Mendez, Miguel Angel Garcia Cabezas, et al.

    This was the first study evaluating the immunogenicity and safety of the quadrivalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) coadministered with routine childhood vaccines in young infants. In this open, randomized, controlled, phase III study (NCT01144663), 2095 infants (ages 6–12 weeks) were randomized (1:1:1:1) into 4 groups to receive MenACWY-TT at 2, 3, 4 and 12 months of age, or MenACWY-TT, MenC-cross-reactive material (CRM197) or MenC-TT at 2, 4 and 12 months of age. All participants received PHiD-CV and DTPa-HBV-IPV/Hib at 2, 3, 4 and 12 months of age. Immune responses were measured by serum bactericidal activity assays using rabbit (rSBA) and human (hSBA) complement. Solicited and unsolicited symptoms were recorded during 8 and 31 days post-vaccination, respectively, and serious adverse events throughout the study. Noninferiority of immune responses to MenC induced by 2 or 3 doses of MenACWY-TT versus 2 doses of MenC-TT or MenC-CRM197 was demonstrated. Predefined criteria for the immunogenicity of MenACWY-TT to MenA, MenW and MenY were met. One month after 2 or 3 primary MenACWY-TT doses, ≥93.1% and ≥88.5% of infants had rSBA and hSBA titers ≥1:8 for all serogroups. The robust increases in rSBA and hSBA titers observed for all vaccine serogroups postbooster vaccination suggested that MenACWY-TT induced immune memory. MenACWY-TT coadministered with childhood vaccines had a clinically acceptable safety profile. This study supports the coadministration of MenACWY-TT with routine childhood vaccines as 2 or 3 primary doses during infancy followed by a booster dose in the second year of life.


  • Foetal bradycardia: A retrospective study in 9 Spanish centres

    by F. Perin, M.M. Rodríguez Vázquez del Rey, L. Deiros Bronte, Q. Ferrer Menduiña, F. Rueda Nuñez, J.I. Zabala Arguelles, D. García de la Calzada, S. Teodoro Marin, F. Centeno Malfaz, A. Galindo Izquierdo

  • Guía clínica para la prevención de la endocarditis infecciosa

    by J. Pérez-Lescure Picarzo, D. Crespo Marcos, F. Centeno Malfaz


  • Open Access

    P88 ‐ Protocol implementation: effect on the assistance quality received by patients

    by Rebeca Mozún‐Torrico, Roberto Velasco‐Zúñiga, Juan Enrique Trujillo‐Wurttele, Sara Martín‐Armentia, Leticia González‐Martín, Fernando Centeno‐Malfaz

  • Open Access

    P70 ‐ Testing adherence to asthma clinical guidelines in Spain

    by Leticia Gonzalez‐Martin, Fernando Centeno‐Malfaz, Roberto Velasco‐Zuñiga, Juan Enrique Trujillo Wurttele, Jose Luis Fernández Arribas, Sara Puente‐Montes, Maria Nathalie Campo‐Fernández, Sara Martin‐Armentia, Rebeca Mozun‐Rico, Elena Perez‐Gutiérrez

  • Five-year Antibody Persistence and Safety Following a Booster Dose of Combined Haemophilus influenzae Type b–Neisseria meningitidis Serogroup C–Tetanus Toxoid Conjugate Vaccine

    by Juan Carlos Tejedor, José Manuel Merino, Manuel Moro, Maria-Luisa Navarro, José Espín, Félix Omeñaca, José García-Sicilia, David Moreno-Pérez, Jesús Ruiz-Contreras, Fernando Centeno, et al.

    Booster vaccination with the combined Haemophilus influenza type b-Neisseria meningitides serogroup C-tetanus toxoid vaccine (Hib-MenC-TT) has been reported to induce different MenC antibody responses depending on the priming vaccines, with a possible impact on long-term protection. Here, the five-year persistence of immune responses induced by a booster dose of Hib-MenC-TT was evaluated in toddlers primed with either Hib-MenC-TT or MenC-TT. This is the follow-up of a phase III, open, randomized study, in which a Hib-MenC-TT booster dose was given at 13.14 months of age to toddlers primed with either 3 doses of Hib-MenC-TT or 2 doses of MenC-TT in infancy. Children in the control group had received 3 primary doses and a booster dose of MenC-CRM197. Functional antibodies against MenC were measured by a serum bactericidal assay with rabbit complement (rSBA-MenC) and antibodies against Hib polyribosylribitol phosphate by enzyme-linked immunosorbent assay. Serious adverse events considered by the investigator to be possibly related to vaccination were to be reported throughout the study. At 66 months postbooster, rSBA-MenC titers ≥8 were retained by 82.6% of children primed with Hib-MenC-TT, 94.1% of children primed with MenC-TT, and 60.9% of children in the control group. All children who received the Hib-MenC-TT booster dose retained anti- polyribosylribitol phosphate concentrations ≥0.15 μg/mL. No serious adverse events considered possibly related to vaccination were reported. There is evidence of good antibody persistence against MenC and Hib for more than five years postbooster vaccination with Hib-MenC TT in toddlers primed with Hib-MenC-TT or MenC-TT.


  • Host and environmental factors influencing respiratory secretion of pro‐wheezing biomarkers in preterm children

    by Vanesa Matías, Laura San Feliciano, Jose E. Fernández, Santiago Lapeña, Estibaliz Garrido, Julio Ardura, Maria José Soga, María Paz Aragón, Ana Remesal, Francisca Benito, et al.

    To cite this article: Matías V, San Feliciano L, Fernández JE, Lapeña S, Garrido E, Ardura J, Soga MJ, Aragón MP, Remesal A, Benito F, Andrés J, Centeno F, Marugán V, Bachiller R, Bermejo‐Martin JF. Host and environmental factors influencing respiratory secretion of pro‐wheezing biomarkers in preterm children. Pediatric Allergy Immunology 2012: 23: 441–447. Cytokines are actively secreted by the respiratory mucosa of preterm children and participate in the pathogenesis of wheezing. This study aimed to identify the factors that could potentially influence respiratory secretion of cytokines in these children. A nasopharyngeal aspirate (NPA) was collected from 77 preterm children 1 yr after birth. NPAs from 14 healthy, 1‐yr‐old term children were collected in parallel. 27 cytokines were measured in the NPAs using a multiplex assay. Multivariate stepwise regression analysis with Bonferroni correction evidenced that the variable [daycare attendance] was associated with higher levels of [monocyte chemoattractant protein‐1 (MCP‐1), IL‐6, vascular endothelial growth factor (VEGF), IL‐1β, IL‐10, tumor necrosis factor (TNF)‐α]; [male sex] with higher levels of (MCP‐1, VEGF, and IL‐1β); [smokers at home] was associated with higher levels of MCP‐1 (p < 0.0013). In turn, [prophylaxis with palivizumab] was associated with lower levels of (IL‐6, IL‐7) (p < 0.0013). All these mediators participate in the pathogenesis of asthma and recurrent wheezing. Preterm children secreted higher levels of chemokines (interferon‐gamma inducible protein‐10, macrophage inflammatory protein‐1α, Eotaxin, MCP‐1), growth factors (platelet‐derived growth factor‐bb, VEGF, fibroblast growth factor‐basic, granulocyte macrophage colony‐stimulating factor), Th1 (IL12, interferon‐γ), Th2 (IL‐9, IL‐13), Th17 (IL‐6, IL‐17) cytokines, and immunomodulatory mediators (IL1RA and granulocyte colony‐stimulating factor) than term children. In conclusion, we have identified for the first time a group of individual and environmental factors influencing respiratory secretion of cytokines in preterm children at the long term after birth. To know these factors could help to prevent the instauration of conditions linked to the appearance of chronic respiratory diseases such as wheezing or asthma.